Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13015496 | 1.00 | NPC1 (0.41) | NPC1TSHRDGAT1RAB9ASMN1; SMN2 | |
| SCHEMBL31276238 | 0.85 | NPC1 (0.43) | NPC1TSHRRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31276144 | 0.83 | NPC1 (0.40) | NPC1TSHRDGAT1MAPT | |
| SCHEMBL13015575 | 0.83 | NPC1 (0.44) | NPC1TSHRRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL31129761 | 0.83 | NPC1 (0.38) | NPC1TSHRDGAT1 | |
| SCHEMBL30702016 | 0.82 | NPC1 (0.34) | NPC1DGAT1MAPT | |
| SCHEMBL27191727 | 0.82 | NPC1 (0.34) | NPC1DGAT1MAPT | |
| SCHEMBL13015577 | 0.82 | NPC1 (0.43) | NPC1LMNAMAPT | |
| SCHEMBL24607798 | 0.81 | NPC1 (0.38) | NPC1TSHRDGAT1 | |
| SCHEMBL31211967 | 0.81 | NPC1 (0.48) | NPC1TSHRRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4615455-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024264017-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4472967-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118525021-A | MALT 1-targeted proteolytic compounds | 上海齐鲁制药研究中心有限公司 | 2024-08-20 | — | — | CN | disclosed |
| CN-117157298-A | Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase 4, preparation method, medicinal composition and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023143249-A1 | PROTEIN DEGRADATION COMPOUND TARGETING MALT1 | 上海齐鲁制药研究中心有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4121043-A1 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4076524-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | NPC1 1390/4885TSHR 70/4885DGAT1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.